These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33421628)

  • 1. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
    Vande Casteele N; Abreu MT; Flier S; Papamichael K; Rieder F; Silverberg MS; Khanna R; Okada L; Yang L; Jain A; Cheifetz AS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):465-467.e2. PubMed ID: 33421628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
    Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
    Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease.
    Barrau M; Duprat M; Veyrard P; Tournier Q; Williet N; Marc Phelip J; Waeckel L; Cheifetz AS; Papamichael K; Roblin X; Paul S
    J Crohns Colitis; 2023 Apr; 17(4):633-643. PubMed ID: 36301958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Guido AJ; Crandall W; Homan E; Dotson J; Maltz RM; Donegan A; Drobnic B; Oates M; Boyle B
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):48-54. PubMed ID: 31503216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study.
    Fuentes-Valenzuela E; García-Alonso FJ; Maroto-Martín C; Juan Casamayor L; Garrote JA; Almendros Muñoz R; De Prado Á; Vara Castrodeza A; Marinero MÁ; Calleja Carbajosa R; Barrio J
    Inflamm Bowel Dis; 2023 Oct; 29(10):1586-1593. PubMed ID: 36617284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
    Sazonovs A; Kennedy NA; Moutsianas L; Heap GA; Rice DL; Reppell M; Bewshea CM; Chanchlani N; Walker GJ; Perry MH; McDonald TJ; Lees CW; Cummings JRF; Parkes M; Mansfield JC; Irving PM; Barrett JC; McGovern D; Goodhand JR; Anderson CA; Ahmad T;
    Gastroenterology; 2020 Jan; 158(1):189-199. PubMed ID: 31600487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
    Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
    Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.
    Rissel F; Cazaubon Y; Saffar S; Altwegg R; Artasone M; Lozano C; Vincent T; Jentzer A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
    Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
    Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease.
    Thomas PWA; Chin PKL; Barclay ML
    Intern Med J; 2021 Mar; 51(3):341-347. PubMed ID: 32043746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease.
    Navajas Hernández P; Mouhtar El Halabi S; González Parra AC; Valdés Delgado T; Maldonado Pérez B; Castro Laria L; Charpentier C; Argüelles-Arias F
    Therap Adv Gastroenterol; 2024; 17():17562848241278145. PubMed ID: 39421002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease.
    Jagt JZ; Holleman KW; Benninga MA; Van Limbergen JE; de Boer NKH; de Meij TGJ
    J Pediatr Gastroenterol Nutr; 2024 Jan; 78(1):57-67. PubMed ID: 38291692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
    Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
    Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
    Sasson AN; Ananthakrishnan AN
    Dig Dis Sci; 2022 Jul; 67(7):3124-3128. PubMed ID: 34117949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.
    Samuels A; Whaley KG; Minar P
    Curr Gastroenterol Rep; 2023 Nov; 25(11):323-332. PubMed ID: 37695555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
    Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO
    Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.
    Lyles JL; Mulgund AA; Bauman LE; Su W; Fei L; Chona DL; Sharma P; Etter RK; Hellmann J; Denson LA; Minar P; Dykes DM; Rosen MJ
    Inflamm Bowel Dis; 2021 Mar; 27(4):482-492. PubMed ID: 32448898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
    Samaan MA; Arkir Z; Ahmad T; Irving PM
    Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α.
    Spencer EA; Dubinsky MC; Kamm MA; Chaparro M; Gionchetti P; Rizzello F; Gisbert JP; Wright EK; Schulberg JD; Hamilton AL; McGovern DPB; Dervieux T
    Front Immunol; 2024; 15():1342477. PubMed ID: 38476237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.